ライフサイエンスコーパス: irritable bowel syndrome

1 sease processes such as neurodegeneration or irritable bowel syndrome.

2 ultimately provide a cure for patients with irritable bowel syndrome.

3 NR1) have been associated with some forms of irritable bowel syndrome.

4 ergrowth participates in the pathogenesis of irritable bowel syndrome.

5 hanced toxin sensitivity in a mouse model of irritable bowel syndrome.

6 psy, ataxia, pain, arrhythmia, myotonia, and irritable bowel syndrome.

7 findings, are nonspecific, and can simulate irritable bowel syndrome.

8 es such as fibromyalgia, chronic fatigue and irritable bowel syndrome.

9 cupuncture is a cost-effective treatment for irritable bowel syndrome.

10 osed inflammatory bowel disease and 877 with irritable bowel syndrome.

11 be cost-effective for those with more severe irritable bowel syndrome.

12 other involving children suffering from the irritable bowel syndrome.

13 tion between infection with Blastocystis and irritable bowel syndrome.

14 rted polymorphisms in the pathophysiology of irritable bowel syndrome.

15 e clearly established a genetic component in irritable bowel syndrome.

16 abdominal pain and cramping in patients with irritable bowel syndrome.

17 tem, such as chemotherapy-induced emesis and irritable bowel syndrome.

18 and has been implicated in diseases such as irritable bowel syndrome.

19 oms, such as those regarded as components of irritable bowel syndrome.

20 patients with inflammatory bowel disease and irritable bowel syndrome.

21 n, Crohn's disease, and diarrhea-predominant irritable bowel syndrome.

22 nted Gli binding and showed association with irritable bowel syndrome.

23 functional diarrhea and diarrhea-predominant irritable bowel syndrome.

24 onin antagonists have a therapeutic role for irritable bowel syndrome.

25 ing cancer therapies and in the treatment of irritable bowel syndrome.

26 patients with functional diarrhea, including irritable bowel syndrome.

27 , no tests are available to reliably rule in irritable bowel syndrome.

28 evels of comorbidity included migraine (33), irritable bowel syndrome (17), functional neurological d

29 The prevalences of irritable bowel syndrome (39.4%) by Rome III criteria an

30 ), 6.78% in Crohn's disease (4/59), 5.82% in irritable bowel syndrome (51/877), and 4.9% in the remai

31 valences (per 100 residents) were stable for irritable bowel syndrome (8.3% and 11.4%, respectively)

32 Of them, 305 (16.5%) had AP-FGD [irritable bowel syndrome = 91(4.9%), functional dyspepsi

33 who are in remission and those who developed irritable bowel syndrome after enteric infection continu

34 in the treatment of constipation-predominant irritable bowel syndrome and chronic constipation.

35 ate the persistence, prevalence, and risk of irritable bowel syndrome and chronic fatigue 6 years aft

36 ing is associated with an increased risk for irritable bowel syndrome and chronic fatigue 6 years lat

37 Although symptomatic irritable bowel syndrome and Crohn's disease patients ha

38 associated with diarrheal conditions such as irritable bowel syndrome and enteric infections.

39 gastrointestinal tract disorders, including irritable bowel syndrome and gastroesophageal reflux dis

40 ter, are at increased risk of postinfectious irritable bowel syndrome and inflammatory bowel disease

41 Colon disorders, including irritable bowel syndrome and inflammatory bowel disease,

42 sit and gut microbial communities, including irritable bowel syndrome and inflammatory bowel disease.

43 long-term effects, including postinfectious irritable bowel syndrome and inflammatory bowel disease.

44 , appeared to be most genetically similar to irritable bowel syndrome and most environmentally simila

45 stion that SIBO may be a causative factor in irritable bowel syndrome and of its constituent symptoms

46 successfully treat constipation-predominant irritable bowel syndrome and recent studies show that ex

47 (EPI) confound interpretation of findings in irritable bowel syndrome and severe renal insufficiency.

48 ysiology, etiology, pathogenesis, diagnosis, irritable bowel syndrome, and IBS.

49 broid food poisoning, histamine intolerance, irritable bowel syndrome, and inflammatory bowel disease

50 These include inflammatory bowel diseases, irritable bowel syndrome, and metabolic (i.e. obesity, n

51 robiota, such as inflammatory bowel disease, irritable bowel syndrome, and metabolic syndrome, to nam

52 of work on MGBA focused on immunomodulation, irritable bowel syndrome, and neurodevelopmental disorde

53 owel diseases, celiac disease, food allergy, irritable bowel syndrome, and--more recently recognized-

54 Many treatments for irritable bowel syndrome are available to those with the

55 titial cystitis/painful bladder syndrome and irritable bowel syndrome) are associated with hyperexcit

56 ders, such as inflammatory bowel disease and irritable bowel syndrome, are associated with exaggerate

57 disorders of colonic motor function, such as irritable bowel syndrome, are much more common.

58 disorders (cardiovascular disease, diabetes, irritable bowel syndrome, asthma, and others).

59 nt evidence to recommend serologic tests for irritable bowel syndrome at this time.

60 to human physiology and to diseases such as irritable bowel syndrome, autism, anxiety, depression, a

61 subjects (aged 24-61 y, 6 men) with NCGS and irritable bowel syndrome (based on Rome III criteria), b

62 al gastrointestinal disorders, most commonly irritable bowel syndrome but also other functional and o

63 nalities with inflammatory bowel disease and irritable bowel syndrome but were focused on associative

64 EC has been implicated in the development of irritable bowel syndrome, but this remains to be confirm

65 ota of patients with constipated-predominant irritable bowel syndrome (C-IBS) displays chronic dysbio

66 ely prescribing antibiotics to patients with irritable bowel syndrome can be endorsed.

67 , management, and role in conditions such as irritable bowel syndrome, chronic fatigue, and autoimmun

68 d costs of ambulatory visits for symptomatic irritable bowel syndrome, chronic functional abdominal p

69 Chronic pain syndromes irritable bowel syndrome, chronic pelvic pain, and fibro

70 ion (95% CI, 2.3-3.2) visits for symptomatic irritable bowel syndrome/chronic abdominal pain, 1.0 mil

71 searched by using medical subject headings ("irritable bowel syndrome;" "colonic diseases, functional

72 in small intestinal bacterial overgrowth in irritable bowel syndrome continues, the utility and spec

73 rome, reactive arthritis, and postinfectious irritable bowel syndrome) contribute considerably to the

74 pain - is common in some disorders, such as irritable bowel syndrome, Crohn's disease and pancreatit

75 ur findings link duplications in TPSAB1 with irritable bowel syndrome, cutaneous complaints, connecti

76 In the exposed group, the prevalence of irritable bowel syndrome decreased by 6.7% (RR, 0.85 [95

77 ease in IBD risk for persons with a previous irritable bowel syndrome diagnosis.

78 opsies were also taken from 16 patients with irritable bowel syndrome diarrhea who comprised the cont

79 est drug to be approved for the treatment of irritable bowel syndrome-diarrhoea is rifaximin, which w

80 expanded from 1946 to December 2014 for IBS, irritable bowel syndrome, diet, treatment, and therapy.

81 tic syndromes', 'Chronic fatigue syndrome', 'Irritable bowel syndrome', 'Fibromyalgia', 'Dopamine and

82 ted with chronic prostatitis/CPPS, including irritable bowel syndrome, fibromyalgia, and chronic fati

83 r directly co-morbid somatic disorders, e.g. irritable bowel syndrome, fibromyalgia, or migraine.

84 This issue provides a clinical overview of irritable bowel syndrome, focusing on diagnosis, treatme

85 d in the setting of differentiating IBD from irritable bowel syndrome, for grading inflammation, to d

86 nter placebo-controlled trial, children with irritable bowel syndrome, functional abdominal pain, or

87 disorders of gut-brain interaction, comprise irritable bowel syndrome, functional dyspepsia, abdomina

88 unctional gastrointestinal disorder, such as irritable bowel syndrome, functional dyspepsia, or funct

89 mechanisms may predispose the individual to irritable bowel syndrome, gastroesophageal reflux diseas

90 (FC), Gastrointestinal Symptoms Rating Scale-Irritable Bowel Syndrome (GSRS-IBS) and Hospital Anxiety

91 he Gastrointestinal Symptom Rating Scale for Irritable Bowel Syndrome (GSRS-IBS) into German and to e

92 red by Gastrointestinal Symptom Rating Scale Irritable Bowel Syndrome (GSRS-IBS) version.

93 antibiotics and concurrently, postinfectious irritable bowel syndrome has been associated with a long

94 Traditionally, irritable bowel syndrome has been considered to be a dis

95 BEST PRACTICE ADVICE 8: Although irritable bowel syndrome has been shown to respond to th

96 treatment options for diarrhoea-predominant irritable bowel syndrome have had not very promising res

97 also collected from 151 patients with CD or irritable bowel syndrome (IBS) (controls).

98 ed by the intestinal mucosa of patients with irritable bowel syndrome (IBS) affect the function of en

99 Irritable bowel syndrome (IBS) affects 7% to 21% of the

100 tudies have shown an increased prevalence of irritable bowel syndrome (IBS) after acute gastroenterit

101 patients (63.8%) had a previous diagnosis of irritable bowel syndrome (IBS) and 23 (28.8%) had one of

102 e Rome IV Diagnostic Questionnaire, Rome III irritable bowel syndrome (IBS) and constipation question

103 es from patients of colorectal cancer (CRC), irritable bowel syndrome (IBS) and controls to be run th

104 We investigated the role of TRPV1 in irritable bowel syndrome (IBS) and evaluated if an antag

105 symptoms, which occasionally mimic those of Irritable Bowel Syndrome (IBS) and Fibromyalgia Syndrome

106 hypnotherapy (HT) is effective in pediatric irritable bowel syndrome (IBS) and functional abdominal

107 tious gastroenteritis increases the risk for irritable bowel syndrome (IBS) and functional dyspepsia

108 ists are effective in treating patients with irritable bowel syndrome (IBS) and have anxiolytic effec

109 The clinical spectra of irritable bowel syndrome (IBS) and inflammatory bowel di

110 Irritable bowel syndrome (IBS) and inflammatory bowel di

111 Abuse history is common in irritable bowel syndrome (IBS) and is associated with gr

112 Very few studies report on the prevalence of irritable bowel syndrome (IBS) and its correlates in the

113 Nowadays irritable bowel syndrome (IBS) and lactose intolerance (

114 Irritable bowel syndrome (IBS) and other functional bowe

115 isease (GERD), functional dyspepsia (FD) and irritable bowel syndrome (IBS) are common functional gas

116 healthy children and pediatric patients with irritable bowel syndrome (IBS) are not well defined.

117 Approximately 1 in ten patients with irritable bowel syndrome (IBS) believe their IBS began w

118 cture is used by patients as a treatment for irritable bowel syndrome (IBS) but the evidence on effec

119 Irritable bowel syndrome (IBS) can be responsible for al

120 Although novel therapies for irritable bowel syndrome (IBS) continue to be developed,

121 pathophysiology, diagnosis, and treatment of irritable bowel syndrome (IBS) convened to audit the cur

122 elationship between giardiasis diagnosis and irritable bowel syndrome (IBS) diagnosis.

123 suggestive of functional dyspepsia (FD) and irritable bowel syndrome (IBS) frequently overlap with t

124 Hypnotherapy for irritable bowel syndrome (IBS) has been used primarily i

125 Only a fraction of patients with irritable bowel syndrome (IBS) have increased perceptual

126 Patients with irritable bowel syndrome (IBS) have increased postprandi

127 odify pain end points in clinical trials for irritable bowel syndrome (IBS) highlights the knowledge

128 igenome, and transcriptome in the context of irritable bowel syndrome (IBS) host physiology.

129 and its degree of overlap with dyspepsia and irritable bowel syndrome (IBS) in Nigeria, a typical Afr

130 care consumption for patients diagnosed with Irritable Bowel Syndrome (IBS) in primary and secondary

131 Irritable bowel syndrome (IBS) is a chronic functional g

132 Irritable Bowel Syndrome (IBS) is a chronic/common condi

133 Irritable Bowel Syndrome (IBS) is a common condition cha

134 Irritable bowel syndrome (IBS) is a common functional ga

135 Irritable bowel syndrome (IBS) is a common gastrointesti

136 Irritable bowel syndrome (IBS) is a common gastrointesti

137 Irritable bowel syndrome (IBS) is a common, symptom-base

138 Irritable bowel syndrome (IBS) is a functional disorder

139 Irritable bowel syndrome (IBS) is a functional gastroint

140 Irritable Bowel Syndrome (IBS) is a functional somatic s

141 Irritable bowel syndrome (IBS) is a gut-brain disorder i

142 Irritable bowel syndrome (IBS) is a heterogeneous disord

143 Irritable bowel syndrome (IBS) is among the most common

144 BACKGROUND & AIMS: Irritable bowel syndrome (IBS) is associated with intest

145 Irritable bowel syndrome (IBS) is characterized by abdom

146 Irritable bowel syndrome (IBS) is characterized by alter

147 Irritable bowel syndrome (IBS) is common but difficult t

148 Irritable bowel syndrome (IBS) is common, affecting 10-2

149 Irritable bowel syndrome (IBS) is more common in patient

150 Irritable bowel syndrome (IBS) is one of the most common

151 Irritable bowel syndrome (IBS) is prevalent in patients

152 Patients with irritable bowel syndrome (IBS) often relate symptoms to

153 Patients with Irritable Bowel Syndrome (IBS) often relate their sympto

154 role of the microbiota in the development of irritable bowel syndrome (IBS) only recently has been co

155 ) signaling pathways have been implicated in irritable bowel syndrome (IBS) pathophysiology.

156 HPA axis response to a visceral stressor in irritable bowel syndrome (IBS) patients and healthy cont

157 efore aversive pelvic visceral distention in irritable bowel syndrome (IBS) patients and their possib

158 Syndrome (FMS) is a frequent comorbidity in Irritable Bowel Syndrome (IBS) patients with a higher fu

159 This study investigated Irritable Bowel Syndrome (IBS) prevalence in a sample of

160 The diagnosis of irritable bowel syndrome (IBS) relies on symptom-based c

161 Irritable bowel syndrome (IBS) remains an incompletely u

162 The pathophysiology of irritable bowel syndrome (IBS) remains enigmatic; abnorm

163 Patients with irritable bowel syndrome (IBS) seen by a gastroenterolog

164 sorbed fermentable carbohydrates can provoke irritable bowel syndrome (IBS) symptoms by escaping abso

165 suspected food intolerances in patients with irritable bowel syndrome (IBS) using confocal laser endo

166 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

167 entable carbohydrates may induce symptoms of irritable bowel syndrome (IBS) via unclear mechanisms.

168 ders state that children suspected of having Irritable Bowel Syndrome (IBS) with Constipation (IBS-C)

169 ept study for the treatment of patients with irritable bowel syndrome (IBS) with constipation (IBS-C)

170 treatments are needed for patients who have irritable bowel syndrome (IBS) with diarrhea.

171 ciated with colonic transit in patients with irritable bowel syndrome (IBS) with diarrhea.

172 showed the benefit of a 5HT(3) antagonist in irritable bowel syndrome (IBS) with diarrhoea (IBS-D) an

173 of PI sequelae among exposed was as follows: irritable bowel syndrome (IBS), 3.0; dyspepsia, 1.8; con

174 and male healthy subjects and patients with irritable bowel syndrome (IBS), a common chronic abdomin

175 d neural mechanisms are well-acknowledged in irritable bowel syndrome (IBS), a disorder of brain-gut-

176 ve been implicated in the pathophysiology of irritable bowel syndrome (IBS), a visceral pain syndrome

177 including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), and chronic constipation

178 in patients with functional dyspepsia (FD), irritable bowel syndrome (IBS), and FD-IBS overlap.

179 s are abnormal in the ileum of patients with irritable bowel syndrome (IBS), and whether any abnormal

180 d genetic factors contribute to variation in irritable bowel syndrome (IBS), anxiety and depression.

181 Certain gut disorders, such as the irritable bowel syndrome (IBS), are associated with elev

182 ND & AIMS: Probiotics can reduce symptoms of irritable bowel syndrome (IBS), but little is known abou

183 bnormal gut-brain interactions are common in irritable bowel syndrome (IBS), but the associations bet

184 Peppermint oil is frequently used to treat irritable bowel syndrome (IBS), despite a lack of eviden

185 iated with three other functional disorders; irritable bowel syndrome (IBS), functional dyspepsia (FD

186 the area of functional GI syndromes such as irritable bowel syndrome (IBS), functional dyspepsia, an

187 ose was to evaluate the overlap frequency of irritable bowel syndrome (IBS), gastroesophageal reflux

188 on ultimate diagnosis: Crohn's disease (CD), Irritable bowel syndrome (IBS), NSAIDs enteritis (NSAIDs

189 een pathophysiologic factors and symptoms of irritable bowel syndrome (IBS), or whether these factors

190 In patients with irritable bowel syndrome (IBS), pain amplification and h

191 patients with functional dyspepsia (FD) and irritable bowel syndrome (IBS), respectively, as defined

192 Using CLE analysis of patients with irritable bowel syndrome (IBS), we found that more than

193 In irritable bowel syndrome (IBS), which is the most common

194 l gastrointestinal symptoms in patients with irritable bowel syndrome (IBS), yet there is limited evi

195 atory bowel diseases (IBD), the reporting of irritable bowel syndrome (IBS)-type symptoms by patients

196 ted to reduce symptoms in some patients with irritable bowel syndrome (IBS).

197 ociated with abdominal pain in patients with irritable bowel syndrome (IBS).

198 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

199 sing diet in the management of patients with irritable bowel syndrome (IBS).

200 effective in the treatment of patients with irritable bowel syndrome (IBS).

201 agonists might be involved in development of irritable bowel syndrome (IBS).

202 by mutations in SCN5A also have symptoms of irritable bowel syndrome (IBS).

203 have important roles in the pathogenesis of irritable bowel syndrome (IBS).

204 the pathophysiology of anxiety disorders and irritable bowel syndrome (IBS).

205 studies of existing diagnostic criteria for irritable bowel syndrome (IBS).

206 microbiota might also play a similar role in irritable bowel syndrome (IBS).

207 relieve symptoms for patients suffering from irritable bowel syndrome (IBS).

208 versus usual care alone for the treatment of Irritable Bowel Syndrome (IBS).

209 important role in the pathophysiology of the irritable bowel syndrome (IBS).

210 used to treat patients with nonconstipating irritable bowel syndrome (IBS).

211 l nervous system is altered in patients with irritable bowel syndrome (IBS).

212 measure patient-reported outcomes (PROs) in irritable bowel syndrome (IBS).

213 he development of drugs for the treatment of irritable bowel syndrome (IBS).

214 nities to develop new therapeutic agents for irritable bowel syndrome (IBS).

215 ial overgrowth (SIBO) may be associated with irritable bowel syndrome (IBS).

216 risk of gastrointestinal diseases including irritable bowel syndrome (IBS).

217 chologic dysfunction have been implicated in irritable bowel syndrome (IBS).

218 regulated in functional GI disorders such as irritable bowel syndrome (IBS).

219 rrhoea and chronic diarrhoea associated with irritable bowel syndrome (IBS).

220 testinal microbiota and clinical features of irritable bowel syndrome (IBS).

221 pulation each year, and is a risk factor for irritable bowel syndrome (IBS).

222 hypersensitivity is common in patients with irritable bowel syndrome (IBS).

223 the progression and evaluate the severity of irritable bowel syndrome (IBS).

224 Visceral hypersensitivity is one feature of irritable bowel syndrome (IBS).

225 in, constipation, and bloating; diagnoses of irritable bowel syndrome (IBS); and tegaserod prescripti

226 alence of celiac disease among patients with irritable bowel syndrome (IBS); few data are available w

227 fies the FBDs into five distinct categories: irritable bowel syndrome (IBS); functional constipation

228 shown promise in alleviating the symptoms of irritable bowel syndrome (IBS); however, controlled data

229 and polyols (FODMAPs) exacerbate symptoms of irritable bowel syndrome (IBS); however, their mechanism

230 red an important pathophysiologic symptom in irritable bowel syndrome (IBS); previous gastrointestina

231 compared to a milk product in subjects with irritable bowel syndrome (IBS, n = 28).

232 in the treatment of constipation predominant irritable bowel syndrome (IBS-C), a highly prevalent dis

233 ogenetics of CDC in constipation-predominant irritable bowel syndrome (IBS-C).

234 Patients with diarrhea-predominant irritable bowel syndrome (IBS-D) could benefit from a gl

235 Management of diarrhoea-predominant irritable bowel syndrome (IBS-D) is generally based on p

236 efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D).

237 ned diarrhea, including diarrhea-predominant irritable bowel syndrome (IBS-D).

238 microbiota transplantation for patients with irritable bowel syndrome in a randomised, double-blind,

239 valuate the effectiveness of acupuncture for irritable bowel syndrome in primary care when provided a

240 ased understanding of the pathophysiology of irritable bowel syndrome in the past 10 years has led to

241 Underlying mechanisms that could lead to irritable bowel syndrome include genetic factors (most n

242 orders including inflammatory bowel disease, irritable bowel syndrome, infectious and antibiotic-asso

243 ith active UC, inactive UC, Crohn's disease, irritable bowel syndrome, infectious colitis, and micros

244 various gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, an

245 nfection, small bowel intestinal overgrowth, irritable bowel syndrome, inflammatory bowel disease, po

246 , including Clostridium difficile infection, irritable bowel syndrome, inflammatory bowel diseases, i

247 Irritable bowel syndrome is a functional gastrointestina

248 risk factor is acute enteric infection, but irritable bowel syndrome is also more common in people w

249 w we challenge the widely accepted view that irritable bowel syndrome is an unexplained brain-gut dis

250 Irritable bowel syndrome is characterized by altered sen

251 Irritable bowel syndrome is classified as a functional g

252 toms and the strong overlap between GERD and irritable bowel syndrome is due to the influence of NERD

253 The pathophysiology of irritable bowel syndrome is incompletely understood, but

254 interventions are enjoying a renaissance in irritable bowel syndrome management.

255 Postinfectious irritable bowel syndrome may occur in 3% to 17% of patie

256 hat patients with symptoms of nonconstipated irritable bowel syndrome (NC-IBS) undergo testing for ce

257 hea and colitis, inflammatory bowel disease, irritable bowel syndrome, necrotizing enterocolitis, and

258 n, Latino individuals, and participants with irritable bowel syndrome or Crohn's disease were more li

259 04-1.1), diarrhea (OR, 53; 95% CI, 6.1-471), irritable bowel syndrome (OR, 4.8; 95% CI, 1.6-14), chol

260 ed to control (P<.001) and disease controls (irritable bowel syndrome; P<.001; rheumatoid arthritis;

261 vergrowth is one of the causes suggested for irritable bowel syndrome, particularly for the diarrhoea

262 een the control group and Crohn's disease or irritable bowel syndrome patients in terms Blastocystis

263 The existence of postinfection irritable bowel syndrome (PI-IBS) has been substantiated

264 Post-infectious irritable bowel syndrome (PI-IBS) is a common gastrointe

265 Post-infectious Irritable Bowel Syndrome (PI-IBS) is a functional bowel

266 he role of gut microbiota in post-infectious irritable bowel syndrome (PI-IBS) is convincing.

267 actor for the development of post-infectious Irritable Bowel Syndrome (PI-IBS).

268 Acupuncture for irritable bowel syndrome provided an additional benefit

269 the gut microbiota and the immune system", "irritable bowel syndrome related to gut microbiota", and

270 Irritable bowel syndrome remains an incompletely underst

271 ith increased rate ratios (RRs) for incident irritable bowel syndrome (RR, 6.1; 95% confidence interv

272 Patients had a greater reduction in irritable bowel syndrome severity scores following the l

273 ficant difference after 4 weeks in change in irritable bowel syndrome severity scores, but significan

274 mens from patients with UC, Crohn's disease, irritable bowel syndrome, sporadic colorectal cancer, or

275 Identical irritable bowel syndrome symptoms are probably due to di

276 o an online database called Transcriptome of Irritable Bowel Syndrome (TIBS).

277 Noninflammatory irritable bowel syndrome was induced by intracolonic ins

278 The term "irritable bowel syndrome" was used to search Clinical Ev

279 chronic fatigue syndrome' and 'Dopamine and irritable bowel syndrome' was carried out until April 20

280 At 6 months, new diagnoses of irritable bowel syndrome were made in 2 patients (1%) an

281 233 patients with irritable bowel syndrome were randomly allocated to eith

282 liaison psychiatric setting in patients with irritable bowel syndrome, where positive benefits have b

283 n important clinical feature associated with irritable bowel syndrome which in some patients has been

284 Irritable bowel syndrome, which affects 5-10% of the pop

285 ion, 15 with functional bloating, and 3 with irritable bowel syndrome with alternating bowel habits)

286 Irritable bowel syndrome with constipation (IBS-C) affec

287 Patients with irritable bowel syndrome with constipation (IBS-C) and p

288 GC-C) that reduces symptoms associated with irritable bowel syndrome with constipation (IBS-C).

289 C) includes functional constipation (FC) and irritable bowel syndrome with constipation (IBS-C).

290 ipation, chronic idiopathic constipation, or irritable bowel syndrome with constipation is often made

291 ith functional intestinal disorders (27 with irritable bowel syndrome with constipation, 15 with func

292 ed by >2 symptoms of chronic constipation or irritable bowel syndrome with constipation, and with >2

293 tion subtypes of functional constipation and irritable bowel syndrome with constipation.

294 Some patients with irritable bowel syndrome with diarrhea (IBS-D) have inte

295 abdominal pain and diarrhea in patients with irritable bowel syndrome with diarrhea (IBS-D) without c

296 a large proportion of people diagnosed with irritable bowel syndrome with diarrhea, a common functio

297 reased loss of bile acids (BAs), overlapping irritable bowel syndrome with diarrhoea (IBS-D).

298 Chronic idiopathic constipation (CC) and irritable bowel syndrome with predominant constipation (

299 Irritable bowel syndrome with predominant constipation (

300 ctional bowel disorders (FBDs), particularly irritable bowel syndrome, with the objective of elucidat